Which non-trastuzumab regimens are used in the treatment of HER2/neu-positive breast cancer?

Updated: Apr 23, 2020
  • Author: Joseph A Sparano, MD; Chief Editor: John V Kiluk, MD, FACS  more...
  • Print
Answer

Answer

Regimens are as follows:

  • TAC: Docetaxel (Taxotere) 75 mg/m2 IV on day 1 plus  doxorubicin (Adriamycin) 50 mg/m2 IV on day 1 plus  cyclophosphamide 500 mg/m2 IV on day 1 every 3 wk for six cycles or

  • Dose-dense ACP: Doxorubicin 60 mg/m2 IV plus  cyclophosphamide 600 mg/m2 every 2wk for four cycles, followed by paclitaxel 175 mg/m2 every 2 wk with CSF support [8]  or

  • AC: Doxorubicin 60 mg/m2 IV plus  cyclophosphamide 600 mg/m2 IV on day 1 every 3wk for four cycles (comparable to CMF) [10]  or

  • TC: Docetaxel 75 mg/m2 IV on day 1 plus  cyclophosphamide 600 mg/m2 IV on day 1 every 3 wk for four cycles


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!